Evidence map›Paper›PMID 33267820›Full record

ArticleBMC cancer2020

Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.

Sho Yasuta, Tatsushi Kobayashi, Hidetoshi Aizawa, Shinichiro Takahashi, Masafumi Ikeda, Masaru Konishi, Motohiro Kojima, Hirofumi Kuno, Katsuhiko Uesaka, Soichiro Morinaga and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Borderline resectable pancreatic cancer: Certainties and controversies.World journal of gastrointestinal surgery · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Sho YasutaDepartment of Hepato-biliary Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Tatsushi KobayashiDepartment of Diagnostic Radiology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. takobaya@east.ncc.go.jp.
Hidetoshi AizawaDepartment of Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Shinichiro TakahashiDepartment of Hepato-biliary Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Masafumi IkedaDepartment of Hepato-biliary Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masaru KonishiDepartment of Hepato-biliary Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Motohiro KojimaDivision of Pathology, National Cancer Center Hospital East, Kashiwa, Japan.
Hirofumi KunoDepartment of Diagnostic Radiology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Katsuhiko UesakaDepartment of Hepato-biliary Pancreatic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Soichiro MorinagaDepartment of Hepato-Biliary and Pancreatic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Atsushi MiyamotoDepartment of Hepato-Biliary-Pancreatic Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Hirochika ToyamaDepartment of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Norihisa TakakuraDepartment of Surgery, Fukuyama City Hospital, Fukuyama, Japan.
Keishi SugimachiDepartment of Hepato-Biliary-Pancreatic Surgery, National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan.
Wataru TakayamaDepartment of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan.
National Cancer Center Hospital East · JPChiba Cancer Center · JPFukuyama City Hospital · JPJichi Medical University · JPKanagawa Cancer CenterKobe University · JPNational Hospital Organization Kyushu Cancer Center · JPOsaka National Hospital · JPShizuoka Cancer Center · JP

Funding

the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development AMED (19ck0106441h0003)
6 · The paper itself

Abstract

backgroundBorderline resectable pancreatic cancer (BRPC) is frequently associated with positive surgical margins and a poor prognosis because the tumor is in contact with major vessels. This study evaluated the relationship between the margin-negative (R0) resection rate and findings indicating peripancreatic vascular invasion on multidetector computed tomography (MDCT) imaging after neoadjuvant chemoradiotherapy (NACRT) in patients with BRPC.

methodsTwenty-nine BRPC patients who underwent laparotomy after neoadjuvant S-1 with concurrent radiotherapy were studied retrospectively. Peripancreatic major vessel invasion was evaluated based on the length of tumor-vessel contact on MDCT. The R0 resection rates were compared between the progression of vascular invasion (PVI) group and the non-progression of vascular invasion (NVI) group.

resultsThere were 3 patients with partial responses (10%), 25 with stable disease (86%), and 1 with progressive disease (3%) according to the RECISTv1.1 criteria. Regarding vascular invasion, 9 patients (31%) were classified as having PVI, and 20 patients (69%) were classified as having NVI. Of the 29 patients, 27 (93%) received an R0 resection, and all the PVI patients received an R0 resection (9/9; R0 resection rate = 100%) while 90% (18/20) of the NVI patients underwent an R0 resection. The exact 95% confidence interval of risk difference between those R0 resection rates was - 10.0% [- 31.7-20.4%].

conclusionsPatients with BRPC after NACRT achieved high R0 resection rates regardless of the vascular invasion status. BRPC patients can undergo R0 resections unless progressive disease is observed after NACRT.

trial registrationUMIN-CTR, UMIN000009172 . Registered 23 October 2012.

Indexed as

AgedFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPancreatic NeoplasmsPrognosisTomography, X-Ray ComputedBorderline resectable pancreatic cancerJASPAC 05Neoadjuvant chemoradiotherapyProgression of vascular invasionR0 resectabilityS-1 and concurrent radiotherapy

Identifiers

PMID33267820
PMCPMC7709301
OpenAlexW3106740304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.